Teaming Up to Take on Cancer
John Theurer Cancer Center. Georgetown Lombardi Comprehensive Cancer Center. Two strong institutions that share a passion and expertise in laboratory research, developing new therapies and understanding cancer at the population level — all to improve outcomes for patients with cancer or to prevent them from getting it in the first place.
Now John Theurer Cancer Center, part of Hackensack University Medical Center in New Jersey, and Georgetown Lombardi Comprehensive Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center in the Washington, D.C. area, are combining forces to take on cancer. Together the two institutions are evaluating novel cancer treatments from their earliest evaluation in phase I studies through late-phase clinical trials aimed at improving existing treatments. As partners, they are evaluating new technologies to accelerate research data exchange and enhance patient outcomes. In addition, they are developing and launching new studies that will provide a greater understanding of the ways in which cancer affects large populations.
A History of Success
John Theurer Cancer Center has an exceptionally strong clinical cancer program and, in 2015, began collaborating with Georgetown Lombardi to re-establish the bone marrow transplant program at MedStar Georgetown University Hospital. These institutions are leading the field in marrow transplantation and research—a treatment approach for which John Theurer Cancer Center is renowned.
Georgetown Lombardi is well-recognized for its robust basic research program and features research initiatives that complement John Theurer Cancer Center’s investigational efforts. Together, the two cancer centers have a synergy fueled by a commitment to pioneering basic scientific and translational research, a wide range of clinical trials, and top-notch clinical care.
A Shared Focus
As partners, focus will center on areas of study with the most potential to improve patient care, including:
- Immunotherapies, which harness the power of the immune system to find and destroy cancer cells.
- Precision medicine, in which innovative drugs are developed which target the molecular signals driving cancer growth and spread.
- Big data analytics that clarify response to therapy and can help doctors choose the most effective treatment for each patient by exploring biomarkers and predictors of response.
- Population health studies aimed at identifying the reasons behind cancer disparities, identifying populations at risk, and improving cancer screening. Between the New York City metropolitan area and Washington, DC, the two cancer centers cover a geographic area that is home to a large percentage of the U.S. population, including residents from every race, ethnic group, and socioeconomic background.
John Theurer Cancer Center and Georgetown Lombardi Comprehensive Cancer Center began their research collaboration in 2015. While maintaining their independence, this strategic collaboration allows both institutions to leverage resources, capabilities, and expertise to accelerate discoveries in cancer research and clinical care. The combined strength also sparks collaborations with other academic cancer centers as well as the pharmaceutical industry.
The shared goal of the research collaboration with Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center fosters combined leadership in basic cancer research and clinical care for the betterment of their patients.